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Abstract
Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed enzymes that ligate amino acids
onto tRNAmolecules. Genes encoding ARSs have been implicated in myriad dominant and reces-
sive disease phenotypes. Glycyl-tRNA synthetase (GARS) is a bifunctional ARS that charges
tRNAGly in the cytoplasm and mitochondria. GARS variants have been associated with domi-
nant Charcot-Marie-Tooth disease but have not been convincingly implicated in recessive phe-
notypes. Here, we describe a patient from the NIH Undiagnosed Diseases Program with a mul-
tisystem, developmental phenotype. Whole-exome sequence analysis revealed that the patient
is compound heterozygous for one frameshift (p.Glu83Ilefs*6) and one missense (p.Arg310Gln)
GARS variant. Using in vitro and in vivo functional studies, we show that bothGARS variants cause
a loss-of-function effect: the frameshift variant results in depleted protein levels and the mis-
sense variant reduces GARS tRNA charging activity. In support ofGARS variant pathogenicity, our
patient shows striking phenotypic overlap with other patients having ARS-related recessive dis-
eases, including features associated with variants in both cytoplasmic and mitochondrial ARSs;
this observation is consistent with the essential function of GARS in both cellular locations. In
summary, our clinical, genetic, and functional analyses expand the phenotypic spectrum associ-
ated withGARS variants.
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1 INTRODUCTION
Aminoacyl-tRNAsynthetases (ARS) are ubiquitously expressed, essen-
tial enzymes that charge tRNA molecules with cognate amino acids—
the first step of cytoplasmic and mitochondrial protein synthesis. The
humannuclear genomeharbors37ARSgenes including17 that encode
a cytoplasmic enzyme, 17 that encode a mitochondrial enzyme, and
three that encode bifunctional enzymes that charge tRNA for pro-
tein synthesis in both cellular locations (Antonellis & Green, 2008).
ARS loci and enzymes are named by the single-letter code for the
amino acid that they charge, plus “ARS” and a variable “2” for enzymes
that charge tRNA exclusively in the mitochondria. For example, AARS
encodes cytoplasmic alanyl-tRNA synthetase and AARS2 encodes the
mitochondrial form of alanyl-tRNA synthetase.
Glycyl-tRNA synthetase (GARS; MIM# 600287) encodes a bifunc-
tional tRNA-charging enzyme that differentially localizes to the cyto-
plasm or mitochondria via two translation start sites that either
include or exclude a mitochondrial targeting sequence (Antonellis
& Green, 2008). GARS variants have been implicated in CMT2D,
an autosomal-dominant, axonal form of Charcot-Marie-Tooth disease
(MIM# 600287) (Antonellis et al., 2003). CMT2D is characterized by
an upper limb predominant peripheral neuropathy that affects motor
and sensory function in the distal extremities (Sivakumar et al., 2005).
Onepatientwith a recessivemitochondrial phenotypewas reported to
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be compound heterozygous for GARSmissense variants: p.Arg596Gln
and p.Ser635Leu (McMillan et al., 2014). However, certain limitations
of the above study indicated that additional analyses were required
to determine the role of GARS variants in recessive disease. First,
the restriction of the phenotype to impaired mitochondrial function
is surprising given the role of GARS in cytoplasmic protein transla-
tion and the severity of fly and mouse phenotypes associated with
biallelic mutations in GARS (Chihara, Luginbuhl, & Luo, 2007; Motley
et al., 2011). Second, the authors of the above study did not provide
functional data supporting the pathogenicity of the variants; enzyme
kinetic analyses were not performed and, indeed, p.Ser635Leu was
previously shown toencodea functionalGARSenzyme (Nangle, Zhang,
Xie, Yang, & Schimmel, 2007). Finally, p.Ser635Leu was previously
shown to not be associatedwith dominant humandisease (Griffin et al.,
2014); however, the variant was not evaluated for a role in recessive
phenotypes. Here,we present clinical, genetic, and functional data that
implicate compound heterozygosity for loss-of-functionGARS variants
in a recessive, earlyonset,multisystem, developmental phenotype.Our
findings expand the phenotypic heterogeneity associated with GARS
variants.
2 MATERIAL AND METHODS
2.1 Clinical evaluation and variant analysis
The proband was admitted to the National Institutes of Health (NIH)
Undiagnosed Diseases Program (UDP) under the protocol 76-HG-
0238, “Diagnosis and Treatment of Patients with Inborn Errors of
Metabolism or Other Genetic Disorders,” approved by the National
Human Genome Research Institute (NHGRI) Institutional Review
Board (IRB). Clinical data were obtained after written informed con-
sent from the proband’s parents. Genomic DNA was extracted from
whole blood using the Gentra Puregene Blood Kit (Qiagen, Hilden,
Germany). Single-nucleotide polymorphism (SNP) analyses were per-
formed using an Illumina Omni Express 12 (hg18) SNP array and the
Genome Studio software program.Whole-exome sequencing was per-
formed using the Illumina HiSeq2000 platform and the TrueSeq cap-
ture kit (Illumina, San Diego, CA) by the NIH Intramural Sequencing
Center (NISC) as described (Bentley et al., 2008; Gahl et al., 2012;
Gnirke et al., 2009; Teer et al., 2010). Sequence data were aligned to
the human reference genome (hg19) using Novoalign (Novocraft Tech-
nologies, Petaling Jaya, Selangor, Malaysia). Variants were analyzed,
sorted, andfilteredwithVarSifter andagraphical java tool to view, sort,
and filter variants (Teer, Green, Mullikin, & Biesecker, 2012). Variants
were filtered based on allele frequencies in the NIH-UDP (Gahl & Tifft,
2011; Gahl et al., 2012; Markello et al., 2012) cohort (<0.06). Variant
annotation is based on NM_002047.3 and each variant was submitted
to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/): c.246_249del with
accessionnumberSCV000579486andc.929G>Awith accessionnum-
ber SCV000579487.
2.2 Protein isolation andwestern blot analysis
Primary fibroblasts from the affected individual and a control indi-
vidual (i.e., bearing no GARS variants) were obtained and utilized for
western blot analysis. Cells were cultured in T-75cm3-treated cell cul-
ture flasks (USA Scientific, Ocala, FL) and maintained at 37◦C and 5%
CO2 in complete medium (Dulbecco’s modified Eagle medium [Invit-
rogen, Carlsbad, CA]) with 10% fetal bovine serum (ThermoFisher
Scientific, Waltham, MA), 1× L-glutamine [(Corning, Corning, NY)],
1× Penicillin-Streptomycin [final concentration 50 units/ml penicillin
and 50 𝜇g/ml streptomycin; ThermoFisher Scientific]). Cells were har-
vested at 90% confluence with 3 ml .25% trypsin (ThermoFisher Sci-
entific), quenched with 7 ml complete cell medium, and collected at
2,000 rpm for 2 min. The resulting pellet was resuspended in 1 ml
cell lysis buffer (RIPA buffer [ThermoFisher Scientific] + 1× EDTA-
free protease inhibitor [ThermoFisher Scientific]) and incubated at 4◦C
for 30 min with gentle shaking. Cell debris was collected at 4◦C and
12,000 rpm for 5 min, and the resulting supernatant was subjected to
western blot analysis.
Total protein concentration was measured using the Thermo Sci-
entific Pierce BCA Protein Assay Kit (ThermoFisher Scientific), and
10 𝜇g protein/sample was analyzed unless otherwise specified. Pro-
tein samples were prepared in 1× SDS-sample buffer (ThermoFisher
Scientific) and 1 𝜇l 2-mercaptoethanol (𝛽ME), denatured at 99◦C for
5 min and separated on a precast 4%–20% tris-glycine protein gel
(ThermoFisher Scientific) at 150 V for 2 hr at room temperature.
Prior to protein transfer, a polyvinylidene difluoride (PVDF) mem-
brane was prewashed in 100% methanol and soaked in 1× trans-
fer buffer (ThermoFisher Scientific) with extra thick blot paper (Bio-
Rad, Hercules, CA) and 3 mm chromatography paper (Whatman PLC,
Maidstone, United Kingdom). Protein was transferred onto the mem-
brane using a Transbot-SD Semi-Dry Transfer Cell (Bio-Rad) at 23V
for 1.5 hr at room temperature and subsequently blocked over night
at 4◦C in blocking solution (1 g dry milk powder, 50 ml 1× TBST
[tris-buffered saline solution and tween 20, pH 7.5]). The membrane
was cut in half and incubated in blocking solution with either anti-
GARS673 antibody (Antonellis et al., 2006) (at 1/2,000 dilution) or anti-
actin antibody (at 1/5,000 dilution [Sigma–Aldrich, St. Louis, MO]) at
room temperature for 1 hr. The membrane was washed three times
in 1× TBST to remove unbound primary antibody and incubated in
blocking solutionwith 10 ng/ml donkey anti-rabbit IgGHRP secondary
antibody (ThermoFisher Scientific) at room temperature for 1 hr. The
membrane was washed three times in 1× TBST to remove unbound
secondary antibody and exposed using SuperSignal West Dura sub-
strate and enhancer (ThermoFisher Scientific). Western blot analy-
sis was repeated four independent times with independent fibroblast
cell lysates and ImageJ (https://imagej.nih.gov/ij/) was used to quantify
band intensity. The analyzed control and affected fibroblast cell lines
were passage-matched (±3 passages).
2.3 Generation of GARS expression constructs
GARS expression constructs were generated using Gateway cloning
technology (Invitrogen). The human GARS open-reading frame was
amplified from human cDNA using primers designed with Gateway
sequences attB1 (forward) and attB2 (reverse; primer sequences
available on request). Entry clones were generated by recombining
PCR-purified amplicons into the pDONR221 vector using BP clonase.
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After transformation into E. coli, DNA from individual entry clones was
isolated and subjected to Sanger sequencing analysis to confirm the
presence of the appropriate wild-type gene. Oligonucleotides-
containing sequences corresponding to the c.929G>A GARS variant
(encoding p.Arg310Gln) were generated and mutagenesis was per-
formed using the QuickChange II XL Site-Directed Mutagenesis Kit
Stratagene (San Diego, CA). After transformation into E. coli, DNA
from individual cloneswas purified and sequenced to confirm the pres-
ence of each variant and the absence of any errors. Validated entry
clones were purified and recombined into a Gateway-compatible
pET-21a(+) vector for aminoacylation assays (Griffin et al., 2014) using
LR clonase. DNA from the resulting expression constructs was purified
and digested with BsrGI New England Biosystems (Waltham, MA) to
confirm the presence of the insert.
For yeast complementation assays, human GARS proteins were
expressed from the pYY1 expression construct containing full-length,
ΔMTS, or ΔMTSΔWHEP GARS, or no insert (empty); these constructs
were a gift from Chin-I Chien and Chien-Chia Wang (National Cen-
tral University, Taiwan) (Chien et al., 2014). We made pYY1 Gateway-
compatible by digesting the empty pYY1 plasmid with SpeI (New Eng-
land Biolabs), blunt-cloning in reading frame cassette A (Invitrogen),
and subsequent transformation into ccdB-resistant E. coli (Invitrogen)
and purification of plasmid DNA. Sanger sequencing confirmed proper
cassette orientation downstream of the ADH1 promoter. To generate
human GARS expression constructs for yeast experiments, the full-
length, ΔMTS, and ΔMTSΔWHEP GARS open-reading frames were
amplified from the initial expression constructs with primers bear-
ing Gateway-flanking sequences. The resulting PCR products were
gel-purified and BP-cloned into the pDONR221 entry vector (Ther-
moFisher Scientific). Sanger sequencing confirmed specificity and lack
of PCR-induced errors. The p.Arg310Gln GARS variant was gener-
ated using the QuickChange II XL Site-Directed Mutagenesis Kit,
a sequence-validated wild-type full-length, ΔMTS, or ΔMTSΔWHEP
GARS pDONR221 template, and variant-specific primers. The reaction
was transformed into E. coli, and plasmid DNA was purified from the
individual colonies and then subjected to Sanger sequencing to confirm
the presence of the variant and the absence of PCR-induced errors. A
sequence-validatedpDONR221construct forwild-typeormutant full-
length,ΔMTS, orΔMTSΔWHEPGARSwasLR-cloned into theGateway
compatible pYY1 construct. The resulting reactions were transformed
into E. coli, purified, and digested with BsrG1 (New England Biolabs)
to confirm the presence of the respective human GARS open-reading
frame.
2.4 Aminoacylation assays
Wild-type and p.Arg310Gln GARS were expressed in E. coli with a C-
terminal His tag and purified with nickel affinity resins (Novagen, Bil-
lerica, MA). The T7 transcript of human tRNAGly/UCU (UCU, anti-
codon) was prepared and purified as previously described (Hou,West-
hof, & Giegé, 1993), heat denatured at 85◦C for 3min, and annealed at
37◦C for 20 min before use. Steady-state aminoacylation assays were
monitored at 37◦C in 50 mM HEPES (pH 7.5), 20 mM KCl, 10 mM
MgCl2, 4 mM DTT, 2 mM ATP, and 50 mM 3H-glycine (Perkin Elmer,
Waltham, MA) at a specific activity of 16,500 dpm/pmole. The reac-
tion was initiated by mixing GARS enzyme (20–600 nM) with vary-
ing concentrations of tRNA (0.3–20 𝜇M). Aliquots of a reaction mix-
ture were spotted on filter paper, quenched by 5% trichloroacetic
acid, washed, dried, and measured for radioactivity using a liquid scin-
tillation counter (LS6000SC; Beckman Coulter Inc, Pasadena, CA).
The amount of radioactivity retained on filter pads was corrected
for quenching effects to determine the amount of synthesis of Gly-
tRNAGly. Steady-state kinetics was determined by fitting the initial
rate of aminoacylation as a function of tRNA concentration to the
Michaelis–Menten equation (Schreier & Schimmel, 1972).
2.5 Yeast complementation assays
Yeast complementation assays were carried out using the haploid S.
cerevisiae strain disrupted for the endogenous GRS1 and maintained
viable via pRS316 bearing wild-type GRS1 (Turner, Lovato, & Schim-
mel, 2000). To assess the ability of wild-type and mutant human
GARS alleles to support cellular growth, the haploid yeast strain was
transformed with wild-type full-length, wild-type ΔMTS, or wild-type
ΔMTSΔWHEP GARS, the corresponding p.Arg310Gln GARS expres-
sion constructs, or empty pYY1 (i.e., bearing no GARS insert) (Chien
et al., 2014). Transformed yeast cells were selected for the presence
of pYY1 by growth on solid media lacking leucine (pYY1 harbors the
LEU2 gene) and uracil (pRS316 harbors theURA3 gene). Colonies were
grown to saturation in 2 ml liquid medium lacking leucine and uracil
(-leu-ura) at 30◦C and shaking at 275 rpm for 48 hr. Each 2 ml satu-
rated culture was spun down at 1,000 rpm and resuspended in 100 𝜇l
UltraPure Rnase/DNase-free water. Undiluted cultures and dilutions
of 1:10, 1:100, and 1:1,000 were spotted on 0.1% 5-FOA complete
solid medium (Teknova, Hollister, CA) to select for cells that sponta-
neously lost the URA3-bearing maintenance vector (Boeke, LaCroute,
& Fink, 1984). Yeast viability was visually assessed after 4 days of incu-
bation at 30◦C. Two colonies per transformation were assayed and
each transformation was repeated twice.
3 RESULTS
3.1 Clinical and genetic analysis of patient
UDP5316
A simplex pedigree was presented to the NIH Undiagnosed Diseases
Program. The proband is a 7-year-old Caucasian female of noncon-
sanguineous German and Polish ancestry with extreme growth retar-
dation and multiple organ involvement as described below. She was
a 1.52-kg infant born at 36 weeks gestation to a 27-year-old G1P0
mother by scheduled Caesarian section due to severe intrauterine
growth retardation beginning at 29 weeks. There were no mater-
nal exposures and maternal weight gain was only 5 pounds. APGAR
scores were 4 and 9 at 1 and 4 min, respectively. Length, weight,
and head circumference were all 50th percentile for 31 weeks ges-
tation. She remained in the NICU for 2 weeks for poor weight
gain.
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TORCH titers (Group B streptococci, toxoplasma, CMV, HSV II)
were negative. HSV I IgG was reported positive (greater than 5),
indicating a previous immunological exposure but the patient did not
show clinical signs of active infection and did not receive treatment;
this might be due to an outbreak of cold sores as reported by the
proband’s mother early in pregnancy. Hepatitis B, hepatitis C, Rubella,
HIV,Herpes, and standardSTDpanelwerenegative.Ophthalmic exam-
ination was normal. An echocardiogram revealed peripheral pulmonic
stenosis.
Despite adequate calories, the child failed to thrive. X-rays at
7 months of age showed cephalofacial disproportion with a large
calvaria, numerous wormian bones, and low-normal bone mineral-
ization. Skull X-ray at 2 years 9 months of age no longer showed
the wormian bones, but the rest of the findings remained the same
(Supp. Fig. S1). Brain MRI at 29 months showed moderate-to-severe
thinning of the corpus callosum, mild atrophy of the cerebellar ver-
mis, and a small brain stem (Fig. 1A). There was decreased cere-
bral white matter volume consistent with delayed myelination (also
observed at 11 months of age; data not shown), and mildly enlarged
ventricles. Cervical X-ray revealed that C5 through C7 were fused
(Fig. 1B). Cardiac evaluation at 4 years identified a moderately sized
atrial septal defect and pulmonic stenosis. A sleep study demonstrated
severe central and obstructive apnea. Recurrent ear and upper res-
piratory infections prompted myringotomy tube placement and pro-
phylactic antibiotic treatments. She continues to suffer from atopic
dermatitis and recurrent rhinitis. Developmentally, the child rolled
at 4 months, sat at 16 months, commando crawled at 10 months,
cruised at 22 months, and walked at 6 years. Fine motor skills include
feeding herself with a pincer grasp at 5 years and holding a pencil
at 5 years. Her verbal skills include 20–25 single words with poor
intelligibility.
On initial NIH evaluation at 2 years 9 months, her weight was 7.6
kg, height was 72 cm, and head circumference was 43 cm. These mea-
sures are all below the 5th percentile for 33 months of age. The child
was microcephalic with a patent anterior fontanelle and sparse, thin
scalp hair. Facial features included a triangular face with broad fore-
head, prominent epicanthal folds, hypotelorism, smooth philtrum, and
a high-arched palate. She was nonambulatory and displayed upper
F IGURE 1 Clinical features of patient UDP5316.A: RepresentativeMRI images for the proband at 29months of age. Cerebral cortex appeared
normal, but there was decreased cerebral white matter volume and delayed myelination (shown in 1, coronal image, T1-weighted), moderate-to-
severe thinning of the corpus callosum,mild atrophy of the cerebellar vermis, small brain stem (shown in 2, sagittal image, T1-weighted), andmildly
enlarged ventricles (axial images; 3, FLAIR; 4, T2-weighted). B: Cervical spine X-ray shows fusion of C5–C7 vertebra. C–E: Growth curves of the
patient plotted in comparison with normal children 0–36months of age; weight (C), height (D), and head circumference (E)
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F IGURE 2 Identification of GARS variants in patient UDP5316. A: The simplex pedigree is shown with squares representing males, circles rep-
resenting females, and diagonal lines representing deceased individuals. Sample numbers and genotypes are indicated under each symbol for the
mother, father, and proband (filled circle). The proband is the only affected individual in the pedigree. B: Representative sequence chromatograms
are shown for the identified variants (protein and cDNA annotations are provided at the top) in the indicated individuals (sample IDs are shown
along the left side). Arrows indicate the position of each variant. C: GARS functional domains are indicated in red (catalytic domain) and green
(anticodon-binding domain), and the position of each variant is shown across the top. Numbers along the bottom indicate amino acid positions.D:
The position of the p.Arg310Gln variant is shown along with flanking amino acid residues for multiple, evolutionarily diverse species. The position
of the affected residue is shown in red for each species
motor neuron signswith hyperreflexia and spasticity of both upper and
lower extremities but normal range ofmotion and hypermobility of her
ankles. She did not have any signs of a lower motor neuron disorder or
neuropathy and her sensation to temperature, light touch, and vibra-
tion were all normal.
Dilated ophthamologic evaluation revealed a normal macula and
vessels but peripheral retinal changes including atrophy and depig-
mentation. Auditory evaluation showed bilateral sensorineural hear-
ing loss.
To identify candidate variants for the unexplained phenotype,
whole-exome sequencing analysis was performed on genomic
DNA isolated from the patient (UDP5316), her unaffected mother
(UDP6340), and her unaffected father (UDP6341) (Fig. 2A). Using a
Boolean sort with parents and proband as heterozygous in VarSifter,
a mean allele frequency of <0.02 (1,000 genomes), and an allele fre-
quency of 0 in the NIH-UDP cohort (Bentley et al., 2008; Gahl & Tifft,
2011; Gahl et al., 2012; Gnirke et al., 2009; Markello et al., 2012; Teer
et al., 2010; Teer et al., 2012), we identified two variants in the gene
encoding hexokinase 3 (HK3) and two variants in the gene encoding
GARS. The HK3 variants were excluded from further analyses because
one variant (c.1733A>G,NM_002115.2; rs61749651) is present in the
exome aggregate (ExAC)/genome aggregate (gnomAD) database (Lek
et al., 2016) at a relatively high frequency (3,862 alleles in 276,696
chromosomes including 54 homozygous genotypes). The GARS vari-
ants (NM_002047.3) include: (1) c.246_249del, which is predicted to
cause an early frameshift variant p.Glu83Ilefs*6; and (2) c.929G>A,
which is predicted to cause a missense variant p.Arg310Gln (Table 1).
The unaffected mother carries p.Glu83Ilefs*6 in the heterozygous
state, the unaffected father carries p.Arg310Gln in the heterozy-
gous state, and the affected proband is compound heterozygous for
both GARS variants (Fig. 2A and B). Neither variant is present in the
ExAC/gnomAD database (Table 1) (Lek et al., 2016). Modeling each of
the identified GARS variants on the primary structure of the protein
revealed that p.Glu83Ilefs*6 is predicted to ablate all key functional
domains of the enzyme (both catalytic domains and the tRNA-binding
domain) and that p.Arg310Gln affects a residue in the catalytic core of
the enzyme (Fig. 2C). Multiple-species conservation analysis revealed
that p.Arg310Gln affects a residue that is conserved among diverse
species including human, mouse, zebrafish, andworm (Fig. 2D).
3.2 p.Glu83Ilefs*6 GARS reduces expression of the
full-length GARS protein
Because p.Gly83IllefsX6 GARS encodes a premature stop codon, the
variant is predicted to ablate the expression of full-lengthGARS,which
would result in a 50% decrease in full-length GARS protein levels in
patient cells. To test this, we performed western blot analysis using
whole-cell lysates fromfibroblasts isolated frompatientUDP5316and
TABLE 1 GARS variants identified in patient UDP5316
Nucleotide changea Amino acid changeb Detection in gnomADc
c.246_249del p.Glu83Ilefs*6 Not present
c.929G>A p.Arg310Gln Not present
aHuman nucleotide positions correspond to GenBank Accession number
NM_002047.3.
bHuman amino acid positions correspond to GenBank Accession number
NP_002038.2.
chttp://gnomad.broadinstitute.org.
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F IGURE 3 The GARS variants identified in patient UDP5316 reduce gene function.A: Western blot analyses were performed with total protein
lysates fromfibroblast cell lines fromunaffected (Control) and affected (UDP5316) patients using an anti-GARS or antiactin antibody, as indicated.
Sample names are across the top and sizes (kDa) are indicated at the left.B: Initial aminoacylation rates (pmole/min) of wild-type (black circles and
line) and p.Arg310Gln GARS (orange circles and line) were plotted against tRNA concentrations and fit to the Michaelis–Menten equation. Error
bars indicate standard deviations.C: Representative cultures of the indicated yeast strains were plated on solid growthmedium containing 5-FOA.
Each strain was previously transfected with a vector containing no insert (empty pYY1), or containing either wild-type or mutant (p.Arg310Gln)
GARS in open-reading frames to express full-length protein (FL), a protein with the mitochondrial targeting sequence deleted (Δ), or a protein
with the mitochondrial targeting sequence and theWHEP domain deleted (ΔΔ). Before inoculating on medium containing 5-FOA, each strain was
diluted 1:10, 1:100, or 1:1,000 in water. Please note the minimal growth associated with the wild-type full-length protein in the undiluted sample,
the intermediate growth associated with the wild-typeΔ protein in the undiluted and 1:10 diluted samples, and the robust growth associatedwith
wild-typeΔΔ protein in all dilutions
from an unaffected control (i.e., a patient negative for GARS variants).
Protein sampleswere electrophoresed, transferredonto aPVDFmem-
brane, and incubated with an anti-GARS antibody (Antonellis et al.,
2006). Our results revealed a∼50% reduction in full-length GARS pro-
tein levels in the patient fibroblast cells compared with the control cell
line (Fig. 2A); a similar assessment of three additional control fibroblast
samples confirmed these findings (Supp. Fig. S2). To confirm the sensi-
tivity of ourwestern blot analysis, we analyzed 20, 10, and 5 𝜇g of total
protein from the control cell lysate with the same antibody and were
able to detect a 50% reduction in protein levels (Fig. 3A). We there-
fore conclude that p.Gly83IllefsX6GARS ablates the expression of full-
length GARS and posit that the remaining protein represents transla-
tion from the p.Arg310GlnGARS allele.
3.3 The p.Arg310Gln GARS variant reduces enzyme
activity
The primary function of GARS is to charge tRNAGly molecules
with glycine in a two-step aminoacylation reaction: (1) binding
and activation of the amino acid with ATP and (2) conjugation of
the activated amino acid to the 3’-end of the appropriate tRNA
(Delarue, 1995). The aminoacylation assay evaluates the completion
of both steps and has been used to establish that CMT2D-associated
variants disrupt GARS enzymatic activity (Griffin et al., 2014; Nangle
et al., 2007). We assessed recombinant human GARS proteins (wild
type and p.Arg310Gln) for the ability to charge human cytoplasmic
tRNAGly with tritium-labeled glycine as previously described (Griffin
et al., 2014). Analysis of the initial rate of aminoacylation as a func-
tion of the tRNA substrate concentration showed that p.Arg310Gln
GARS demonstrates less than 1% aminoacylation activity compared
with wild-type GARS (Fig. 3B; Table 2) indicating that it is a hypomor-
phic allele.
3.4 The p.Arg310Gln GARS variant does not
support yeast cell growth in complementation assays
Yeast complementation assays have been employed to reveal loss-
of-function characteristics of CMT2D-associated GARS variants
(Antonellis et al., 2006; Griffin et al., 2014). While previous efforts
employed the yeast ortholog of GARS (GRS1) to assess human variants
(Antonellis et al., 2006;Griffin et al., 2014; Turner et al., 2000), a recent
study showed that three engineered isoforms of the humanGARS pro-
teinwere able to rescue deletion ofGRS1: (1) full-lengthGARS allowed
minimal cell growth; (2) GARS with the mitochondrial targeting
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TABLE 2 Kinetic analysis of p.Arg310Gln GARS
Variant kcat (s
−1) Km(𝝁M) kcat/Km (s
−1
𝝁M−1) Ratio
Wild type 0.049± 0.014 0.74± 0.30 0.066 1
p.Arg310Gln 0.00040± 1.0× 10−4 5.5± 2.2 7.2× 10−5 1/920
sequence deleted (ΔMTS) allowed intermediate cell growth; and (3)
GARS with both the MTS andWHEP domain deleted (ΔMTSΔWHEP)
allowed robust cell growth (Chien et al., 2014) (the function of the
WHEP domain has not been defined but it is not essential for enzyme
activity [Chang, Chien, Chang, Lin, & Wang, 2016]). We therefore
evaluated the effect of the p.Arg310Gln GARS variant in all three
of the above GARS isoforms. Briefly, the wild-type or p.Arg310Gln
GARS open-reading frames (full-length, ΔMTS, or ΔMTSΔWHEP)
were cloned downstream of the yeast ADH1 promoter (Chien et al.,
2014), and yeast complementation assays were performed using a
haploid yeast strain deleted for the endogenous GRS1 locus (ΔGRS1);
this strain carries wild-type GRS1 on a URA3-bearing maintenance
vector to maintain viability (Turner et al., 2000). Wild-type or mutant
GARS expression constructs, or one with no GARS insert (“Empty”
in Fig. 3C), were introduced into the above strain, and growth was
subsequently evaluated on medium containing 0.1% 5-FOA, which
selects for the spontaneous loss of the maintenance vector (Boeke
et al., 1984). All of the wild-type human GARS expression constructs
supported yeast growth, whereas the empty plasmid did not (Fig. 3C),
consistent with human GARS supporting loss of the endogenous GRS1
locus and with GRS1 being an essential gene. In contrast, none of the
p.Arg310GlnGARS expression constructs supported yeast cell growth,
consistent with this being a loss-of-function allele (Fig. 3C). Combined,
our functional studies indicate that p.Gly83IllefsX6 GARS represents
a null allele and that p.Arg310Gln GARS represents a hypomorphic
allele.
4 DISCUSSION
Twenty-eight ARS loci encoding mitochondrial, cytoplasmic, and
bifunctional ARS enzymes have been implicated in myriad dominant
and recessive human diseases (Oprescu, Griffin, Beg, & Antonellis,
2017). GARS variants cause autosomal-dominant, axonal Charcot-
Marie-Tooth disease (CMT2D) (Antonellis et al., 2003) but have
not been convincingly implicated in recessive phenotypes. Here, we
present clinical, genetic, and functional data that implicate GARS vari-
ants in a severe, multisystem, developmental phenotype. Our func-
tional studies indicate that p.Gly83IllefsX6 GARS ablates the expres-
sion of full-length GARS and that p.Arg310Gln GARS represents a
severely hypomorphic allele. It is important to note that aminoacy-
lation and yeast complementation assays were previously employed
to implicate loss-of-function variants at other ARS loci in recessive
diseases similar to the phenotype described here (please see below):
aminoacylation assays have been used to study disease-associated
variants at 15 ARS loci and yeast complementation assays have been
used to study disease-associated variants at eight ARS loci (Oprescu
et al., 2017). Therefore, our informative and relevant functional anal-
yses support the pathogenicity of p.Gly83IllefsX6 and p.Arg310Gln
GARS in the phenotype reported here.
Careful clinical comparisons between our patient and previously
reportedpatientswithARS-associated recessivephenotypes (Oprescu
et al., 2017) reveals remarkable overlap, further supporting the
pathogenicity of the GARS variants reported here. For example, ARS
genes have been associated with the following recessive phenotypes:
(1) growth retardation in patients with AARS (MIM# 601065), IARS
(MIM#600709),MARS (MIM#156560),MARS2 (MIM#609728),QARS
(MIM# 603727), VARS2 (MIM# 612802), and YARS (MIM# 603623)
variants; (2) microcephaly in patients with AARS, IARS, KARS (MIM#
601421), NARS2 (MIM# 612803), PARS2 (MIM# 612036),QARS, VARS
(MIM# 192150), and VARS2 variants; (3) thinning of the corpus callo-
sum in patients with AARS2 (MIM# 612035), CARS2 (MIM# 612800),
EARS2 (MIM# 612799), FARS2 (MIM# 611592), KARS, QARS, TARS2
(MIM# 612805), VARS, YARS, and YARS2 (MIM# 610957) variants;
(4) decreased white matter in patients with KARS and QARS variants;
(5) brain stem involvement in patients with DARS2 (MIM# 610956),
QARS, and RARS2 (MIM# 611524) variants; (6) spasticity in patients
with AARS, DARS, FARS2, IARS,MARS2, and RARS (MIM# 107820) vari-
ants; and (7) sensorineural hearing loss in patients with CARS2, HARS2
(MIM# 600783), IARS, IARS2 (MIM# 612801), KARS, LARS2 (MIM#
604544), andMARS2 variants.
The recessive disorders caused by variants in the three bifunctional
ARSs appear to sharemore clinical phenotypes comparedwith all ARS-
associated disorders as a whole. Our patient shares many features
with patients who are compound heterozygous for glutaminyl-tRNA
synthetase (QARS) (Zhang et al., 2014) or lysyl-tRNA synthetase
(KARS) variants (McLaughlin et al., 2010; McMillan et al., 2015;
Santos-Cortez et al., 2013). Specifically, our patient shares growth
retardation, microcephaly, thinning of the corpus callosum, decreased
white matter, and brain stem involvement (all noted above), as well as
large calvaria, cerebellar vermis atrophy, dysmorphic features, promi-
nent epicanthal folds, hypotelorism, high-arched palate, delayedmotor
milestones, apnea, and sparse thin scalp hair with patients carrying
loss-of-function QARS variants. Our patient also shares microcephaly,
thinning of the corpus callosum, decreased white matter, and sen-
sorineural hearing loss (all noted above), as well as dysmorphic
features and delayed motor development with patients carrying loss-
of-function KARS variants. These observations are significant since
GARS, QARS, and KARS compose the three bifunctional ARSs that
charge tRNA in the cytoplasm and mitochondria (Antonellis & Green,
2008). In summary, the clinical features of our patient compared with
other patients with ARS variants and our functional studies showing
that p.Gly83IllefsX6 and p.Arg310Gln dramatically impair GARS
function both support the conclusion that compound heterozygosity
for loss-of-function GARS variants results in the severe, multisystem,
developmental phenotype reported here.
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Loss-of-function missense variants in GARS have been associated
with CMT2D, which is characterized by distal muscle weakness and
sensory loss that is predominant in the upper extremities (Antonel-
lis et al., 2003; Sivakumar et al., 2005). Interestingly, neither parent
of the affected proband currently displays signs of CMT2D; EMG and
nerve conduction studies performed on both parents were unremark-
able at ages 30 (mother) and 32 (father); these ages are well beyond
the average age of onset for CMT2D, which is typically in the second
decade of life (Sivakumar et al., 2005). With regard to the mother who
carries the null allele (p.Gly83IllefsX6), this is perhaps not surprising
since haploinsufficiency is not a likely mechanism of GARS-associated
CMT2D;mice heterozygous for a null allele have no detectable pheno-
type, whereasmice heterozygous for amissense variant presentwith a
dominant neuropathy (Motley et al., 2011; Seburn,Nangle, Cox, Schim-
mel, & Burgess, 2006). In contrast, p.Arg310Gln GARS shows features
of CMT2D-associated variants (Griffin et al., 2014); it is a missense
variant in the catalytic domain that affects tRNA-charging capacity.
Two possible explanations for this discrepancy are the reduced pene-
trance ofGARS variants as seen for p.Glu71Gly and p.Leu129ProGARS
(Sivakumar et al., 2005) and the poorly defined mechanism of CMT2D
(i.e., p.Arg310GlnGARSmaybea loss-of-functionmissense variant that
is not dominantly toxic to peripheral nerve axons). Addressing this dis-
crepancy will require animal models and molecular studies to deter-
mine whether, for example, p.Arg310Gln GARS inappropriately binds
neuropilin-1, which has been observed for certain CMT2D-causing
variants (He et al., 2015).
In conclusion, we present clinical, genetic, and functional data that
associate GARS variants with a severe, multisystem, developmental
phenotype. This report exemplifies the growingnumber ofARS loci and
alleles implicated in recessive human diseases (Oprescu et al., 2017),
expands the phenotypic heterogeneity associated with GARS variants,
and underscores the importance of employing careful clinical compar-
isons and informative functional studies to support the pathogenicity
of newly identified ARS variants.
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